The ADCC induced by the cetuximab and IL-2 or IL-15 combination was more evident, since the combination reduced the xenograft tumor volume with an increase in infiltrating NK cells, whereas no significant induction of direct antiproliferative effects on the tumor was observed [370]. This evidence concerns the gene IL2 and neoplasm.